The Wall Street Journal – A Big, Fatty Opportunity for Big Pharma.
CNBC – The $35 billion race to cure a silent killer that affects 30 million Americans.
Nonalcoholic steatohepatitis (NASH), the progressive form of Non-alcoholic fatty liver disease (NAFLD), can lead to cirrhosis, cardiovascular problems, hepatocellular carcinoma, and even death. Liver disease is reversible if detected early on. If diagnosed in advanced stages, it often cannot be cured.
Livivos’s technology transforms liver disease diagnostics, responding to a fast-growing demand for effective and broadly available testing. LiverScope® will significantly advance liver testing on a larger scale and will support accurate evaluation of the response to treatments.
Other liver disease diagnostic modalities are invasive, expensive or inaccurate:
There are 64 million individuals with NAFLD in the United States and 52 million total in Germany, France, Italy, and the UK. The global prevalence of NAFLD is estimated to be 24%. 1.75 million individuals die of liver disease each year. In addition, a high prevalence of obesity has been reported in South America, Asia, and the Middle East. The number of affected people and the economic burden are expected to increase.
Preventive medicine, clinical triage for the millions of patients with suspected NAFLD, and accurate over-time treatment monitoring.
Supporting regulatory clinical trials. There is a rapid increase in the number of liver disease drugs undergoing FDA evaluation. Livivos’s technology provides biomarkers to quantify the evolution of steatosis.
Monitoring of drug effectiveness after drug approval – especially for NASH drugs with anti-steatotic mechanisms of action – as they enter the clinical market.